Exam 1 Drugs Flashcards
Chlorpheniramine
- 1st Generation H1 Histamine Receptor Antagonist
- Alkylamine (mild to moderate sedative) class
- OTC allergy; cold
Diphenhydramine
- 1st Generation H1 Histamine Receptor Antagonist
- Ethanolamine (marked sedative) class
- OTC Sleep Aid; allergies
Promethazine
- 1st Generation H1 Histamine Receptor Antagonist
- Phenothiazine (marked sedative) class
- Antiemetic
Cetirizine
- 2nd Generation H1 Histamine Receptor Antagonist
2. OTC; some sedation
Desloratadine
- 2nd Generation H1 Histamine Receptor Antagonist
Fexofenadine
- 2nd Generation H1 Histamine Receptor Antagonist
2. Active metabolite of terfenadine, which was pulled from the market due to propensity to cause cardiac arrhythmias
Loratadine
- 2nd Generation H1 Histamine Receptor Antagonist
2. OTC
Cimetidine
- H2 Histamine Receptor Antagonist
2. Inhibits CYP450; may cause confusion in elderly patients with large dose
Ranitidine
- H2 Histamine Receptor Antagonist
2. Less effect on CYP450
PGE2
- Prostaglandin
- Involved in uterine contraction, fever, GI smooth muscle contraction, pain, mucus secretion, inhibition of gastric secretion and pepsin content
Misoprostol
- Prostaglandin
2. PGE1 analog; should be co-administered with NSAID for patients at risk for GI toxicity
Montelukast
- Leukotriene Antagonist
2. Used in bronchiole asthma
Zafirlukast
- Leukotriene Antagonist
2. Used in bronchiole asthma
Acetaminophen
- Inhibits COX (mechanism unclear)
- Antipyretic and Analgesic
- Toxicity: Metabolite formed by oxidation via P450 in liver conjugates with Glutathione; large doses deplete Glutathione causing hepatotoxicity
- Prescriptions limited to 325 mg per tablet
Aspirin
- NSAID; irreversible inhibitor (acetylation) of COX
- Low dose: inhibits platelet aggregation; Moderate dose: analgesic and antipyretic effects; Large dose: anti-inflammatory/antirheumatoid effects
Diclofenac
- NSAID; acetic acid class
2. Treats RA
Diflunisal
- NSAID; nonacetylated class
- Dose-dependent pharmacokinetics
- Used as loading dose
- Treats RA
Ibuprofen
- NSAID; propionic acid class
2. T1/2 = 2 hours; mostly renal elimination
Indomethacin
- NSAID; acetic acid class
- Potent COX inhibitor; direct effects on PMNs; reduces antihypertensive benefits; GI and CNS effects
- Treats RA, Gout pain and inflammation
Naproxen
- NSAID; proprionic acid class
- T1/2 = 12-14 hours; hepatic elimination
- Pediatic use; treats RA
Piroxicam
- NSAID; Enolic Acid class
2. T1/2 = ~50 hours
Sulindac
- NSAID; acetic acid class
- Prodrug; active sulfide metabolite
- Approved for use in pediatric patients
Celecoxib
- NSAID; COX-2 Selective Inhibitor
- 2C9 substrate
- Treats RA
N-Acetylcysteine
- Treatment for Acetaminophen Overdose
Prednisone
- Corticosteroid; Immunosuppresant
- No topical activity; short acting
- MOA: Nuclear hormone receptor family; complex translocated to nucleus, binding as homodimer to DNA transcripts w/ GREs
- Uses: anti-inflammatory, transplant rejection, RA, SLE, systemic dermatomyositis, Psoriasis, asthma and other allergic disorders
- Toxicity: Iatrogenic Cushing’s Syndrome, mineralocorticoid effects @ high doses (heart disease), prolonged therapy (inf., inh. growth, induce myopathy, osteoporosis, cataracts), >2 weeks can induce adrenal suppression (adrenocortical atrophy)
Dexamethasone
- Corticosteroid; Immunosuppresant
- Has topical activity; long acting
- MOA: Nuclear hormone receptor family; complex translocated to nucleus, binding as homodimer to DNA transcripts w/ GREs
- Uses: anti-inflammatory, transplant rejection, RA, SLE, systemic dermatomyositis, Psoriasis, asthma and other allergic disorders
- Toxicity: Iatrogenic Cushing’s Syndrome, mineralocorticoid effects @ high doses (heart disease), prolonged therapy (inf., inh. growth, induce myopathy, osteoporosis, cataracts), >2 weeks can induce adrenal suppression (adrenocortical atrophy)
Cyclosporin A (Cyclosporine)
- Calcineurin Inhibitor; Immunosuppresant; lipid-soluble peptide
- ROA: oral, IV, opthalmic emulsion
- MOA: binds Cyclophilin C –> decreases calcineurin (cytoplasmic phosphatase) –> decreases production of cytokines (IL-2) –> reduced response of Tcells to Ags
- Uses: GvH disease in bone marrow transplantation, aplastic anemia, transplant rejection, autoimmune diseases, dry eye syndrome
- Toxicity: reversible nephrotoxicity (dose-limiting), vasconstriction leading to HTN, neurotoxicity, hyperlipidemia, transient hepatotoxicity, stimulates TGF-beta which increases risk of cancer
- Interactions: metabolized by P450; erythromycin, ketoconazole, amphotericin B, and grapefruit juice inhbit metabolism; phenobarbital and rifampin increase clearance
Tacrolimus (FK506)
- Calcineurin Inhibitor; Immunosuppresant; Macrolide
- ROA: oral or injection; 10-100x more potent
- MOA: binds FKBP-12 –> inhibits calcineurin –> decreases production of cytokines (IL-2) –> reduced response of Tcells to Ags
- Uses: same as Cyclosporine (except dry eye syndrome)
- Toxicity & Interactions: same as Cyclosporine
Sirolimus
- Antiproliferative Agent; Macrocyclic Lactone; Immunosuppresant
- ROA: oral
- MOA: binds FKBP-12 –> inhibits mTOR –> inhibits T cell activation and proliferation
- Uses: transplant rejection (w/ calc inh. + glucocorticoid), GvH rxn, autoimmune diseases, effect persists several months after end therapy
- Toxicity: dose-dependent thrombocytopenia, leukopenia, hyperlipidemia (esp. renal transplant pts), anemia, hypotension, hypo/hyperkalemia, fever, GI effects, increased risk of lymphoma or inf
- Interactions: same as Cyclosporine
Azathioprine
- Cytotoxic Agent; Immunosuppresant; 6-MP derivative
- ROA: oral or IV
- MOA: inhibits S phase of cell division; converted to thioinosinic acid –> competitive inhibitor of purine synthesis; affects T cells more than B cells
- Uses: transplant rejection (w/ corticosteroid), RA
- Toxicity: bone marrow suppression, GI toxicity, mild hepatotoxicity, may lead to sever inf. + neoplasia
- Interactions: Allopurinol increases toxicities
Mycophenoate Mofetil
- Cytotoxic Agent; Immunosuppresant; produrg
- ROA: oral or IV
- MOA: inhibits monophosphate dehydrogenase –> decreases purine synthesis –> decreases proliferation of B + T cells
- Uses: Allogenic renal transplant rejection (w/ cyclosporine+corticosteroids) and liver, cardiac transplant rejection
- Toxicity: diarrhea, leukopenia, cytomegalovirus inf., GI hemorrhage
- Interactions: Antacids decrease absorption
Fingolimod (FTY720)
- SIP-R Agonist; Immunosuppresant
- ROA: oral
- MOA: “Lymphocyte homing;” reversibly sequesters lymphocytes in lymph nodes and Peyer’s patches –> reducing recirculation of T cells
- Uses: relapsing MS
- Toxicity: decreases HR and/or AV conduction after 1st dose, inf., macular edema, decrease pulmonary function, hepatotoxicity, fetal risk
- Interactions: antiarrhythmic + beta blockers (risk of additive effect on HR), clearance inhibited by ketoconazole (CYP4F inhibitor), avoid live attenuated vaccines
Antithymocyte Globulin (ATG)
- Cytotoxic Antibody
- ROA: oral
- MOA: Ab against T cell surface molecules (CD + HLA) –> block their function, deplete T cells from blood and thymus-dependent areas of spleen and lymph nodes
- Uses: Renal allograph rejection (alone or w/ corticosteroid + azathioprine)
- Toxicity: hypersensitivity, hypotension, nephritis, anaphylaxis (rare), inf.
Muromonab-CD3
- Anti-CD3 Monoclonal Antibody
- MOA: binds CD3 glycoprotein on T cells –> blocks antigen recognition complex –> unable to recognize foreign Ag
- Uses: acute kidney/hepatic transplant rejection, prophylaxis in cardiac transplant, depletion of Tcells in marrow b4 bone marrow transplant
- Toxicity: fever, pulmonary edema, vomiting, headache, anaphylaxis, inf w/ chronic therapy
Basiliximab
- IL-2 Receptor (Anti-CD25) Antibody
- MOA: block IL-2 receptors on activated T cells
- Uses: Acute renal transplant rejection (w/ cyclosporine + corticosteroids)
Daclizumab
- IL-2 Receptor (Anti-CD25) Antibody
- MOA: block IL-2 receptors on activated T cells
- Uses: Acute renal transplant rejection (w/ cyclosporine + corticosteroids)
Infliximab
- Chimeric anti-TNF-alpha monoclonal antibody
- MOA: competitively binds TNF-alpha, preventing it from activating its receptors
- Uses: RA (w/ Methotrexate), Crohn’s disease
- Toxicity: infusion rxn (fever, urticaria, hypotension, dyspnea), URI, UTI, development of antinuclear Abs, with (rare) lupus-like syndrome
Etanercept
- Contains ligand-binding sequence of a human TNF-alpha receptor fused to human IgG1
- MOA: binds TNF-alpha, preventing it from activating its receptors
- Uses: RA
- Toxicity: injection site rxn, inf.
Rh0 (d) Immune Globulin
- MOA: blocks the Ab response of an Rh-negative mother to an Rh-positive baby
- Uses: prevention of hemolytic disease of Rh-positive newborns
Immune globulin
- Immunostimulant; human plasma from donors
- Uses: provide passive immunization for 1-3 months]
- Toxicity: anaphylactoid rxn and severe hypotension, poss. risk of inf.
Methotrexate
- Folic Acid Analog; Antimetabolite; Choice DMARD for RA
- Inhibits enzyme for purine metabolism –> decreased PMN chemotaxis, decreased lymphocyte and macrophage function
- Oral, absorbed from GI
- Nausea and mucosal ulcers, “hypersensitivity” lung reaction
- Take w/folic acid supplements to protect GI and liver. Not for pregnancy
Adalimunab
- IgG anti-TNF-alpha monoclonal antibody
subcutaneous administration –> complex with soluble TNF, decreased macrophage and T cell function - RA, psoriatic arthritis, ankylosing spondylitis
- Deccreased bone erosions
- Increased risk of macrophage dependent infection (TB), maybe vasculitis or leukopenias
Allopurinol
- Inhibitor of Uric Acid Synthesis; treats Gout
- Especially useful in patients with renal insufficiency or calculi
- not useful for acute attacks
- long lasting inhibitor of xantine oxidase
- Drug interactions: ampicillin, thiazides, inhibits oxidation of mercaptopurine to azathioprine, increases toxicity of other cytotoxic drugs (cyclophosphamide)
- Stevens–Johnson syndrome can occur
Febuxostat
- Non-purine like selective inhibitor of xanthine oxidase; treats Gout
- Rapidly and extensively absorbed following oral administration, peak plasma level reached within 1 hr
- May produce GI intolerance/hepatic alterations
- administered orally
- use prophylactic NSAIDs or Colchicine at beginning to prevent gout attack
Probenecid/Sulfinpyrazone
- Uricosuric Agent; treats Gout
- Generally well tolerated by most patients. May produce GI intolerance, dermatitis,nephrotic syndrome (rare)
- orally administered
- with small doses of salicytes = less of an effect
- with large doses of salicytes = more of an effect
- give with colchicine to prevent gout attack
Colchicine
Classification: Acute gouty arthritis
MOA: binds tubulin –> inhibition of leukocyte migration and urate crystal phagocytosis
Use: For Gout Pain and Inflammation
Resistance:
Administration: Oral (at signs of attack), IV
Rasburicase
- For increasing Uric Acid degradation; treats Gout
- catalyzes uric acid conversion to allantoin
- lowers urate levels better than allopurinol
- Recommended for the initial management of hyperuricemia in pediatric patients with cancer chemotherapy-caused increased uric acid production
- problems with production of antibodies, acute renal failure, anaphylaxis, and GI abnormalities
Penicillin G
- Cell wall synthesis inhibitor
- Natural penicillin
- Narrow spectrum
- Orally administered
Penicillin V
- Cell wall synthesis inhibitor
- Synthetic penicillin
- Narrow spectrum
- Orally administered
Oxacillin
cell wall synthesis inhibitor; narrow spectrum
- anti-staph (isoxazolyl penicillins)
Dicloxacillin
cell wall synthesis inhibitor, narrow spectrum
- anti-staph (isoxazolyl penicillins)
Ampicillin
cell wall synthesis inhibitor; amino penicillin
broad spectrum; bactericidal
Amoxicillin
cell wall synthesis inhibitor; amino penicillin
broad specturm, bactericidal
Ticarcillin
cell wall synthesis inhibitor; carboxy penicillin
broad spectrum; bactericidal
Mezlocillin
cell wall synthesis inhibitor; acylureido penicillin
bactericidal; broad spectrum
Clavulanate
Beta-lactamase inhibitor
- oral; renal excretion
Sulbactam
Beta-lactamase inhibitor
- IV, renal excretion
Tazobactam
Beta-lactamase inhibitor
- IV, renal excretion
- pipercillin increases its half life
Cefazolin
1st Generation Cephalosporin (narrow spectrum)
1. Inhibit cell wall synthesis by blocking transpeptidase (no cross linking)
Cephalexin
1st Generation Cephalosporin (narrow)
1. Inhibit cell wall synthesis by blocking transpeptidase (no cross linking)
Cefuroxime
2nd Generation Cephalosporin (broad)
1. Inhibit cell wall synthesis by blocking transpeptidase (no cross linking)
Cefoxitin
2nd Generation Cephalosporin (Broad)
1. Inhibit cell wall synthesis by blocking transpeptidase (no cross linking)
Cefixime
3rd Generation Cephalosporin (broad)
1. Inhibit cell wall synthesis by blocking transpeptidase (no cross linking)
Cefoperazone
3rd Generation Cephalosporin (Broad)
- Inhibit cell wall synthesis by blocking transpeptidase (no cross linking)
- Antipseudomonal
Cefotaxime
3rd Generation Cephalosporin (broad)
1. Inhibit cell wall synthesis by blocking transpeptidase (no cross linking)
Ceftriaxone
3rd Generation Cephalosporin (broad)
1. Inhibit cell wall synthesis by blocking transpeptidase (no cross linking)